Second generation CB1 receptor blockers and other inhibitors of peripheral endocannabinoid overactivity and the rationale of their use against metabolic disorders

Expert Opinion on Investigational Drugs

Volumn 21, Issue 9, 2012, Pages 1309-1322

  Silvestri, Cristoforo ^a   Di Marzo, Vincenzo ^a  

^a CNR   (Italy)

Author keywords

Endocannabinoid; Metabolic disorder; Neutral agonism antagonism; Peripheral restriction

Indexed keywords

1 (2,4 DICHLOROPHENYL) 4 METHYL 5 [5 (5 PENT 1 YNYL)THIOPHEN 2 YL] N (PIPERIDIN 1 YL) 1H PYRAZOLE 3 CARBOXAMIDE; 1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; 3 (1 METHANESULFONYLAMINO 4 HEXYN 6 YL) 6A,7,10,10A TETRAHYDRO 6,6,9 TRIMETHYL 6H DIBENZO[B,D]PYRAN; 4 (4 FLUOROPHENYL)PIPERIDIN 4 OL DERIVATIVE; 5 (4 CHLOROPHENYL) 1 (2,4 DICHLOROPHENYL) 3 HEXYL 1H 1,2,4 TRIAZOLE; 5 (4 CHLOROPHENYL) 3 (2 CYCLOHEXYLETHENYL) 1 (2,4 DICHLOROPHENYL) 4 METHYL 1H PYRAZOLE; 5 [4 (4 CYANOBUT 1 YNYL)PHENYL] 1 (2,4 DICHLOROPHENYL) 4 METHYL N (1,1 DIOXOTHIOMORPHOLINO) 1H PYRAZOLE 3 CARBOXAMIDE; [4 AMINO 1 (4 CHLOROBENZYL) 2 METHYL 5 PHENYL 1H PYRROL 3 YL](PHENYL)METHANONE; AM 4113; AM 6527; AM 6545; BPR 0432; CANNABINOID 1 RECEPTOR AGONIST; CANNABINOID 1 RECEPTOR ANTAGONIST; CANNABINOID RECEPTOR ANTAGONIST; COMPOUND 2C; DELTA8 TETRAHYDROCANNABINOL; ENDOCANNABINOID; ESTERASE INHIBITOR; G PROTEIN COUPLED RECEPTOR; LH 21; OMEGA 3 FATTY ACID; RIMONABANT; UNCLASSIFIED DRUG; URB 447;

ABDOMINAL OBESITY; BINDING AFFINITY; BLOOD BRAIN BARRIER; BODY MASS; CENTRAL NERVOUS SYSTEM; DRUG ACTIVITY; DRUG MECHANISM; FEEDING; HEART DISEASE; HUMAN; METABOLIC DISORDER; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PERIPHERAL NERVOUS SYSTEM; RECEPTOR AFFINITY; REVIEW; RISK FACTOR; UPREGULATION; WEIGHT GAIN;

ANIMALS; CANNABINOID RECEPTOR ANTAGONISTS; DRUG DESIGN; DRUG INVERSE AGONISM; ENDOCANNABINOIDS; HUMANS; METABOLIC DISEASES; OBESITY, ABDOMINAL; PIPERIDINES; PYRAZOLES; RECEPTOR, CANNABINOID, CB1; RISK FACTORS;

EID: 84865335261     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2012.704019     Document Type: Review

References (119)

1. Expert Panel on the Identification E, and Treatment of Overweight in Adults. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: executive summary. expert panel on the identification, evaluation, and treatment of overweight in adults. Am J Clin Nutr 1998; 68(4):899-917
2. WHO. Global strategy on diet, physical activity and health: obesity and overweight. 2012.Available from: http://www.who.int/dietphysicalactivity/ publications/facts/obesity/en/
3. Flegal KM, Carroll MD, Ogden CL, Curtin LR. Prevalence and trends in obesity among US adults, 1999-2008. JAMA 2010;303(3):235-41
4. Malnick SD, Knobler H. The medical complications of obesity. QJM 2006;99(9):565-79 (Pubitemid 44540533)
5. Mechoulam R. Discovery of endocannabinoids and some random thoughts on their possible roles in neuroprotection and aggression. Prostaglandins Leukot Essent Fatty Acids 2002;66(2-3):93-9 (Pubitemid 34743588)
6. Pertwee RG. Cannabinoid pharmacology: the first 66 years. Br J Pharmacol 2006;147(Suppl 1):S163-71 (Pubitemid 43077274)
7. Di Marzo V. Endocannabinoids: synthesis and degradation. Rev Physiol Biochem Pharmacol 2008;160:1-24
8. De Petrocellis L, Cascio MG, Di Marzo V. The endocannabinoid system: a general view and latest additions. Br J Pharmacol 2004;141(5):765-74 (Pubitemid 38446177)
9. Di Marzo V, Petrosino S. Endocannabinoids and the regulation of their levels in health and disease. Curr Opin Lipidol 2007;18(2):129-40 (Pubitemid 46412082)
10. Matias I, Bisogno T, Di Marzo V. Endogenous cannabinoids in the brain and peripheral tissues: regulation of their levels and control of food intake. Int J Obes (Lond) 2006;30(Suppl 1):S7-S12
11. Kirkham TC. Cannabinoids and appetite: food craving and food pleasure. Int Rev Psychiatry 2009;21(2):163-71
12. Kirkham TC, Williams CM, Fezza F, Di Marzo V. Endocannabinoid levels in rat limbic forebrain and hypothalamus in relation to fasting, feeding and satiation: stimulation of eating by 2-arachidonoyl glycerol. Br J Pharmacol 2002;136(4):550-7 (Pubitemid 34717699)
13. Di Marzo V, Goparaju SK, Wang L, et al. Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature 2001;410(6830):822-5 (Pubitemid 32303781)
14. Wiley JL, Burston JJ, Leggett DC, et al. CB1 cannabinoid receptor-mediated modulation of food intake in mice. Br J Pharmacol 2005;145(3):293-300 (Pubitemid 40896074)
15. Poirier B, Bidouard JP, Cadrouvele C, et al. The anti-obesity effect of rimonabant is associated with an improved serum lipid profile. Diabetes Obes Metab 2005;7(1):65-72
16. Ravinet Trillou C, Arnone M, Delgorge C, et al. Anti-obesity effect of SR141716, a CB1 receptor antagonist, in diet-induced obese mice. Am J Physiol Regul Integr Comp Physiol 2003;284(2):R345-53 (Pubitemid 36120150)
17. Cota D, Marsicano G, Tschop M, et al. The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. J Clin Invest 2003;112(3):423-31 (Pubitemid 38063771)
18. Ravinet Trillou C, Delgorge C, Menet C, et al. CB1 cannabinoid receptor knockout in mice leads to leanness, resistance to diet-induced obesity and enhanced leptin sensitivity. Int J Obes Relat Metab Disord 2004;28(4):640-8 (Pubitemid 38491158)
19. Di Marzo V, Matias I. Endocannabinoid control of food intake and energy balance. Nat Neurosci 2005;8(5): 585-9 (Pubitemid 40594198)
20. Bensaid M, Gary-Bobo M, Esclangon A, et al. The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells. Mol Pharmacol 2003;63(4):908-14 (Pubitemid 36368998)
21. Matias I, Gonthier MP, Orlando P, et al. Regulation, function, and dysregulation of endocannabinoids in models of adipose and beta-pancreatic cells and in obesity and hyperglycemia. J Clin Endocrinol Metab 2006;91(8):3171-80 (Pubitemid 44271774)
22. Matias I, Petrosino S, Racioppi A, et al. Dysregulation of peripheral endocannabinoid levels in hyperglycemia and obesity: effect of high fat diets. Mol Cell Endocrinol 2008;286(1-2 Suppl 1):S66-78
23. Pagotto U, Marsicano G, Cota D, et al. The emerging role of the endocannabinoid system in endocrine regulation and energy balance. Endocr Rev 2006;27(1):73-100 (Pubitemid 43228239)
24. Osei-Hyiaman D, DePetrillo M, Pacher P, et al. Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. J Clin Invest 2005;115(5):1298-305 (Pubitemid 40629049)
25. Jourdan T, Djaouti L, Demizieux L, et al. CB1 antagonism exerts specific molecular effects on visceral and subcutaneous fat and reverses liver steatosis in diet-induced obese mice. Diabetes 2010;59(4):926-34
26. Quarta C, Bellocchio L, Mancini G, et al. CB(1) signaling in forebrain and sympathetic neurons is a key determinant of endocannabinoid actions on energy balance. Cell Metab 2010;11(4):273-85
27. Monteleone P, Matias I, Martiadis V, et al. Blood levels of the endocannabinoid anandamide are increased in anorexia nervosa and in binge-eating disorder, but not in bulimia nervosa. Neuropsychopharmacology 2005;30(6):1216-21 (Pubitemid 40720981)
28. Engeli S, Bohnke J, Feldpausch M, et al. Activation of the peripheral endocannabinoid system in human obesity. Diabetes 2005;54(10):2838-43 (Pubitemid 41401077)
29. Cote M, Matias I, Lemieux I, et al. Circulating endocannabinoid levels, abdominal adiposity and related cardiometabolic risk factors in obese men. Int J Obes (Lond) 2007;31(4):692-9 (Pubitemid 46482358)
30. Bluher M, Engeli S, Kloting N, et al. Dysregulation of the peripheral and adipose tissue endocannabinoid system in human abdominal obesity. Diabetes 2006;55(11):3053-60 (Pubitemid 44923642)
31. Bordicchia M, Battistoni I, Mancinelli L, et al. Cannabinoid CB1 receptor expression in relation to visceral adipose depots, endocannabinoid levels, microvascular damage, and the presence of the Cnr1 A3813G variant in humans. Metabolism 2010;59(5):734-41
32. Hajer GR, van Haeften TW, Visseren FL. Adipose tissue dysfunction in obesity, diabetes, and vascular diseases. Eur Heart J 2008;29(24):2959-71
33. Despres JP, Lemieux I. Abdominal obesity and metabolic syndrome. Nature 2006;444(7121):881-7 (Pubitemid 46024995)
34. Silvestri C, Ligresti A, Di Marzo V. Peripheral effects of the endocannabinoid system in energy homeostasis: adipose tissue, liver and skeletal muscle. Rev Endocr Metab Disord 2011;12(3):153-62
35. Mancini G, Quarta C, Srivastava RK, et al. Adipocyte-specific CB1 conditional knock-out mice: new insights in the study of obesity and metabolic syndrome.
36. Osei-Hyiaman D, Liu J, Zhou L, et al. Hepatic CB1 receptor is required for development of diet-induced steatosis, dyslipidemia, and insulin and leptin resistance in mice. J Clin Invest 2008;118(9):3160-9
37. Pagano C, Pilon C, Calcagno A, et al. The endogenous cannabinoid system stimulates glucose uptake in human fat cells via phosphatidylinositol 3-kinase and calcium-dependent mechanisms. J Clin Endocrinol Metab 2007;92(12):4810-19 (Pubitemid 350223464)
38. Ruby MA, Nomura DK, Hudak CS, et al. Overactive endocannabinoid signaling impairs apolipoprotein E-mediated clearance of triglyceride-rich lipoproteins. Proc Natl Acad Sci USA 2008;105(38):14561-6
39. Despres JP, Ross R, Boka G, et al. Effect of rimonabant on the high-triglyceride/ low-HDL-cholesterol dyslipidemia, intraabdominal adiposity, and liver fat: the ADAGIO-Lipids trial. Arterioscler Thromb Vasc Biol 2009;29(3):416-23
40. Di Marzo V, Cote M, Matias I, et al. Changes in plasma endocannabinoid levels in viscerally obese men following a 1 year lifestyle modification programme and waist circumference reduction: associations with changes in metabolic risk factors. Diabetologia 2009;52(2):213-17
41. Jeong WI, Osei-Hyiaman D, Park O, et al. Paracrine activation of hepatic CB1 receptors by stellate cell-derived endocannabinoids mediates alcoholic fatty liver. Cell Metab 2008;7(3):227-35 (Pubitemid 351285525)
42. Jbilo O, Ravinet-Trillou C, Arnone M, et al. The CB1 receptor antagonist rimonabant reverses the diet-induced obesity phenotype through the regulation of lipolysis and energy balance. Faseb J 2005;19(11):1567-9 (Pubitemid 41279033)
43. Tedesco L, Valerio A, Cervino C, et al. Cannabinoid type 1 receptor blockade promotes mitochondrial biogenesis through endothelial nitric oxide synthase expression in white adipocytes. Diabetes 2008;57(8):2028-36
44. Flamment M, Gueguen N, Wetterwald C, et al. Effects of the cannabinoid CB1 antagonist, rimonabant, on hepatic mitochondrial function in rats fed a high fat diet. Am J Physiol Endocrinol Metab 2009;297(5):E1162-70
45. Kola B, Hubina E, Tucci SA, et al. Cannabinoids and ghrelin have both central and peripheral metabolic and cardiac effects via AMP-activated protein kinase. J Biol Chem 2005;280(26):25196-201 (Pubitemid 40934612)
46. Cavuoto P, McAinch AJ, Hatzinikolas G, et al. Effects of cannabinoid receptors on skeletal muscle oxidative pathways. Mol Cell Endocrinol 2007;267(1-2):63-9
47. Tedesco L, Valerio A, Dossena M, et al. Cannabinoid receptor stimulation impairs mitochondrial biogenesis in mouse white adipose tissue, muscle, and liver: the role of eNOS, p38 MAPK, and AMPK pathways. Diabetes 2010;59(11):2826-36
48. Abdul-Ghani MA, DeFronzo RA. Pathogenesis of insulin resistance in skeletal muscle. J Biomed Biotechnol 2010;2010:476279
49. Nogueiras R, Veyrat-Durebex C, Suchanek PM, et al. Peripheral, but not central, CB1 antagonism provides food intake-independent metabolic benefits in diet-induced obese rats. Diabetes 2008;57(11):2977-91
50. Perwitz N, Fasshauer M, Klein J. Cannabinoid receptor signaling directly inhibits thermogenesis and alters expression of adiponectin and visfatin. Horm Metab Res 2006;38(5):356-8 (Pubitemid 43864960)
51. Gary-Bobo M, Elachouri G, Scatton B, et al. The cannabinoid CB1 receptor antagonist rimonabant (SR141716) inhibits cell proliferation and increases markers of adipocyte maturation in cultured mouse 3T3 F442A preadipocytes. Mol Pharmacol 2006;69(2): 471-8 (Pubitemid 43121944)
52. Despres JP, Golay A, Sjostrom L. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 2005;353(20):2121-34 (Pubitemid 41653104)
53. Lindborg KA, Teachey MK, Jacob S, Henriksen EJ. Effects of in vitro antagonism of endocannabinoid- 1 receptors on the glucose transport system in normal and insulin-resistant rat skeletal muscle. Diabetes Obes Metab 2010;12(8):722-30
54. Esposito I, Proto MC, Gazzerro P, et al. The cannabinoid CB1 receptor antagonist rimonabant stimulates 2-deoxyglucose uptake in skeletal muscle cells by regulating the expression of phosphatidylinositol-3-kinase. Mol Pharmacol 2008;74(6):1678-86
55. Lipina C, Stretton C, Hastings S, et al. Regulation of MAP kinase-directed mitogenic and protein kinase B-mediated signaling by cannabinoid receptor type 1 in skeletal muscle cells. Diabetes 2010;59(2):375-85
56. Greasley PJ, Clapham JC. Inverse agonism or neutral antagonism at G-protein coupled receptors: a medicinal chemistry challenge worth pursuing? Eur J Pharmacol 2006;553(1-3):1-9 (Pubitemid 44794497)
57. Pertwee RG. Inverse agonism and neutral antagonism at cannabinoid CB1 receptors. Life Sci 2005;76(12):1307-24
58. Giraldo J. How inverse can a neutral antagonist be? Strategic questions after the rimonabant issue. Drug Discov Today 2010;15(11-12):411-15
59. Sink KS, Vemuri VK, Wood J, et al. Oral bioavailability of the novel cannabinoid CB1 antagonist AM6527: effects on food-reinforced behavior and comparisons with AM4113. Pharmacol Biochem Behav 2009;91(3):303-6
60. Chambers AP, Vemuri VK, Peng Y, et al. A neutral CB1 receptor antagonist reduces weight gain in rat. Am J Physiol Regul Integr Comp Physiol 2007;293(6):R2185-93 (Pubitemid 350224010)
61. Sink KS, McLaughlin PJ, Wood JA, et al. The novel cannabinoid CB1 receptor neutral antagonist AM4113 suppresses food intake and food-reinforced behavior but does not induce signs of nausea in rats. Neuropsychopharmacology 2008;33(4):946-55 (Pubitemid 351252707)
62. Sink KS, Segovia KN, Collins LE, et al. The CB1 inverse agonist AM251, but not the CB1 antagonist AM4113, enhances retention of contextual fear conditioning in rats. Pharmacol Biochem Behav 2010;95(4):479-84
63. Sink KS, Segovia KN, Sink J, et al. Potential anxiogenic effects of cannabinoid CB1 receptor antagonists/ inverse agonists in rats: comparisons between AM4113, AM251, and the benzodiazepine inverse agonist FG-7142. Eur Neuropsychopharmacol 2010;20(2):112-22
64. Cluny NL, Chambers AP, Vemuri VK, et al. The neutral cannabinoid CB receptor antagonist AM4113 regulates body weight through changes in energy intake in the rat. Pharmacol Biochem Behav 2011;97(3):537-43
65. Limebeer CL, Vemuri VK, Bedard H, et al. Inverse agonism of cannabinoid CB1 receptors potentiates LiCl-induced nausea in the conditioned gaping model in rats. Br J Pharmacol 2010;161(2):336-49
66. Bostrom J, Olsson RI, Tholander J, et al. Novel thioamide derivatives as neutral CB1 receptor antagonists. Bioorg Med Chem Lett 2010;20(2):479-82
67. Hurst DP, Lynch DL, Barnett-Norris J, et al. N-(piperidin-1-yl)-5-(4- chlorophenyl)-1-(2, 4-dichlorophenyl)-4- methyl-1H-pyrazole -3-carboxamide (SR141716A) interaction with LYS 3.28 (192) is crucial for its inverse agonism at the cannabinoid CB1 receptor. Mol Pharmacol 2002;62(6):1274-87 (Pubitemid 35403823)
68. Fride E, Braun H, Matan H, et al. Inhibition of milk ingestion and growth after administration of a neutral cannabinoid CB1 receptor antagonist on the first postnatal day in the mouse. Pediatr Res 2007;62(5):533-6 (Pubitemid 351338985)
69. Mechoulam R, Berry EM, Avraham Y, et al. Endocannabinoids, feeding and suckling-from our perspective. Int J Obes (Lond) 2006;30(Suppl 1):S24-8
70. Tseng SL, Hung MS, Chang CP, et al. Bioisosteric replacement of the pyrazole 5-aryl moiety of N-(piperidin-1-yl)-5- (4-chlorophenyl)-1-(2, 4-dichlorophenyl)- 4-methyl-1H-pyrazole -3-carboxamide (SR141716A). A novel series of alkynylthiophenes as potent and selective cannabinoid-1 receptor antagonists. J Med Chem 2008;51(17):5397-412
71. Lin Y, Shia KS, Hsiao WC, et al. Biphasic suppression of appetite by cannabinoid CB1 receptor antagonists with distinct functional activities. Pharmacol Res 2010;62(4):337-43
72. Shim JY, Welsh WJ, Cartier E, et al. Molecular interaction of the antagonist N-(piperidin-1-yl)-5-(4-chlorophenyl)-1- (2, 4-dichlorophenyl)-4- methyl-1Hpyrazole- 3-carboxamide with the CB1 cannabinoid receptor. J Med Chem 2002;45(7):1447-59 (Pubitemid 34246108)
73. Higuchi S, Irie K, Mishima S, et al. The cannabinoid 1-receptor silent antagonist O-2050 attenuates preference for high-fat diet and activated astrocytes in mice. J Pharmacol Sci 2010;112(3):369-72
74. Sano K, Koushi E, Irie K, et al. Delta (9)-tetrahydrocannabinol enhances an increase of plasma corticosterone levels induced by forced swim-stress. Biol Pharm Bull 2009;32(12):2065-7
75. Wiley JL, Breivogel CS, Mahadevan A, et al. Structural and pharmacological analysis of O-2050, a putative neutral cannabinoid CB(1) receptor antagonist. Eur J Pharmacol 2011;651(1-3):96-105
76. Bertalovitz AC, Ahn KH, Kendall DA. Ligand Binding Sensitivity of the Extracellular Loop Two of the Cannabinoid Receptor 1. Drug Dev Res 2010;71(7):404-11
77. Gardner A, Mallet PE. Suppression of feeding, drinking, and locomotion by a putative cannabinoid receptor 'silent antagonist'. Eur J Pharmacol 2006;530(1-2):103-6 (Pubitemid 43037130)
78. Makwana R, Molleman A, Parsons ME. Evidence for both inverse agonism at the cannabinoid CB1 receptor and the lack of an endogenous cannabinoid tone in the rat and guinea-pig isolated ileum myenteric plexus-longitudinal muscle preparation. Br J Pharmacol 2010;160(3):615-26
79. 7TM Pharma press release. Available from: http://www.7tm.dk/News.aspx
80. Fridberg M, Little PB, Cooper M, et al. A single ascending dose study of TM38837 - a novel second generation peripheral selective CB1 receptor antagonist in healthy male subjects. 2010
81. Receveur JM, Murray A, Linget JM, et al. Conversion of 4-cyanomethylpyrazole- 3-carboxamides into CB1 antagonists with lowered propensity to pass the blood-brain-barrier. Bioorg Med Chem Lett 2010;20(2):453-7
82. Jagerovic N, Hernandez-Folgado L, Alkorta I, et al. Discovery of 5-(4- chlorophenyl)-1-(2, 4-dichlorophenyl)-3- hexyl-1h-1, 2, 4-triazole, a novel in vivo cannabinoid antagonist containing a 1, 2, 4-triazole motif. J Med Chem 2004;47(11):2939-42 (Pubitemid 38656746)
83. Pavon FJ, Serrano A, Perez-Valero V, et al. Central versus peripheral antagonism of cannabinoid CB1 receptor in obesity: effects of LH-21, a peripherally acting neutral cannabinoid receptor antagonist, in Zucker rats. J Neuroendocrinol 2008;20(Suppl 1):116-23 (Pubitemid 351552685)
84. Pavon FJ, Bilbao A, Hernandez-Folgado L, et al. Antiobesity effects of the novel in vivo neutral cannabinoid receptor antagonist 5-(4- chlorophenyl)-1-(2, 4-dichlorophenyl)-3- hexyl-1H-1, 2, 4-triazole-LH. Neuropharmacology 2006;51(2):358-66 (Pubitemid 44081792)
85. Alonso M, Serrano A, et al. Anti-obesity efficacy of LH-21, a cannabinoid CB(1) receptor antagonist with poor brain penetration, in diet-induced obese rats. Br J Pharmacol 2012;165(7):2274-2291
86. Chen RZ, Frassetto A, Lao JZ, et al. Pharmacological evaluation of LH-21, a newly discovered molecule that binds to cannabinoid CB1 receptor. Eur J Pharmacol 2008;584(2-3):338-42
87. LoVerme J, Duranti A, Tontini A, et al. Synthesis and characterization of a peripherally restricted CB1 cannabinoid antagonist, URB447, that reduces feeding and body-weight gain in mice. Bioorg Med Chem Lett 2009;19(3):639-43
88. DiPatrizio NV, Astarita G, Schwartz G, et al. Endocannabinoid signal in the gut controls dietary fat intake. Proc Natl Acad Sci USA 2011;108(31):12904-8
89. Son MH, Kim HD, Chae YN, et al. Peripherally acting CB1-receptor antagonist: the relative importance of central and peripheral CB1 receptors in adiposity control. Int J Obes (Lond) 2010;34(3):547-56
90. Tam J, Vemuri VK, Liu J, et al. Peripheral CB1 cannabinoid receptor blockade improves cardiometabolic risk in mouse models of obesity. J Clin Invest 2010;120(8):2953-66
91. Cluny NL, Vemuri VK, Chambers AP, et al. A novel peripherally restricted cannabinoid receptor antagonist, AM6545, reduces food intake and body weight, but does not cause malaise, in rodents. Br J Pharmacol 2010;161(3):629-42
92. Jarbe TU, LeMay BJ, Vemuri VK, et al. Central mediation and differential blockade by cannabinergics of the discriminative stimulus effects of the cannabinoid CB1 receptor antagonist rimonabant in rats. Psychopharmacology (Berl) 2011;216(3):355-65
93. Randall PA, Vemuri VK, Segovia KN, et al. The novel cannabinoid CB1 antagonist AM6545 suppresses food intake and food-reinforced behavior. Pharmacol Biochem Behav 2010;97(1):179-84
94. Kunos G. Peripheral CB1 receptor inverse agonism is equieffective with global CB1 blockade in reversing diet-induced obesity and its metabolic complications. 5th Diabetes Drug Discovery & Development; Boston, MA, USA: 2012
95. Hortala L, Rinaldi-Carmona M, Congy C, et al. Rational design of a novel peripherally-restricted, orally active CB(1) cannabinoid antagonist containing a 2, 3-diarylpyrrole motif. Bioorg Med Chem Lett 2010;20(15):4573-7
96. Hung MS, Chang CP, Li TC, et al. Discovery of 1-(2, 4-dichlorophenyl)-4- ethyl-5-(5-(2-(4-(trifluoromethyl)phenyl) ethynyl)thiophe n-2-yl)-N-(piperidin- 1- yl)-1H-pyrazole-3-carboxamide as a potential peripheral cannabinoid-1 receptor inverse agonist. ChemMedChem 2010;5(9):1439-43
97. Fulp A, Bortoff K, Zhang Y, et al. Towards rational design of cannabinoid receptor 1 (CB1) antagonists for peripheral selectivity. Bioorg Med Chem Lett 2011;21(19):5711-14
98. Fulp A, Bortoff K, Seltzman H, et al. Design and synthesis of cannabinoid receptor 1 antagonists for peripheral selectivity. J Med Chem 2012;55(6):2820-34
99. Cottrell GT, Ferguson AV. Sensory circumventricular organs: central roles in integrated autonomic regulation. Regul Pept 2004;117(1):11-23 (Pubitemid 37548394)
100. Van Sickle MD, Oland LD, Mackie K, et al. Delta9-tetrahydrocannabinol selectively acts on CB1 receptors in specific regions of dorsal vagal complex to inhibit emesis in ferrets. Am J Physiol Gastrointest Liver Physiol 2003;285(3):G566-76 (Pubitemid 37021816)
101. Partosoedarso ER, Abrahams TP, Scullion RT, et al. Cannabinoid1 receptor in the dorsal vagal complex modulates lower oesophageal sphincter relaxation in ferrets. J Physiol 2003;550(Pt 1):149-58 (Pubitemid 36869276)
102. Ahima RS, Saper CB, Flier JS, Elmquist JK. Leptin regulation of neuroendocrine systems. Front Neuroendocrinol 2000;21(3):263-307 (Pubitemid 30495784)
103. Agudo J, Martin M, Roca C, et al. Deficiency of CB2 cannabinoid receptor in mice improves insulin sensitivity but increases food intake and obesity with age. Diabetologia 2010;53(12):2629-40
104. Deveaux V, Cadoudal T, Ichigotani Y, et al. Cannabinoid CB2 receptor potentiates obesity-associated inflammation, insulin resistance and hepatic steatosis. PLoS One 2009;4(6):e5844
105. Bisogno T, Burston JJ, Rai R, et al. Synthesis and pharmacological activity of a potent inhibitor of the biosynthesis of the endocannabinoid 2-arachidonoylglycerol. ChemMedChem 2009;4(6):946-50
106. Jung KM, Clapper JR, Fu J, et al. 2-arachidonoylglycerol signaling in forebrain regulates systemic energy metabolism. Cell Metab 2012;15(3):299-310
107. Bisogno T, Cascio MG, Saha B, et al. Development of the first potent and specific inhibitors of endocannabinoid biosynthesis. Biochim Biophys Acta 2006;1761(2):205-12
108. Schuchardt JP, Schneider I, Meyer H, et al. Incorporation of EPA and DHA into plasma phospholipids in response to different omega-3 fatty acid formulations-a comparative bioavailability study of fish oil vs. krill oil. Lipids Health Dis 2011;10:145
109. Kinsella JE.. Lipids, membrane receptors, and enzymes: effects of dietary fatty acids. JPEN J Parenter Enteral Nutr 1990;14(5 Suppl):200S-17S (Pubitemid 20317200)
110. Matias I, Carta G, Murru E, et al. Effect of polyunsaturated fatty acids on endocannabinoid and N-acyl-ethanolamine levels in mouse adipocytes. Biochim Biophys Acta 2008;1781(1-2):52-60
111. Alvheim AR, Malde MK, Osei-Hyiaman D, et al. Dietary Linoleic Acid Elevates Endogenous 2-AG and Anandamide and Induces Obesity. Obesity (Silver Spring) 2012; doi:10.1038/oby.2012.38.
112. Di Marzo V, Griinari M, Carta G, et al. Dietary krill oil increases docosahexaenoic acid and reduces 2-arachidonoylglycerol but not N-acylethanolamine levels in the brain of obese Zucker rats. Int Dairy J 2010;20(4):231-5
113. Banni S, Carta G, Murru E, et al. Krill oil significantly decreases 2-arachidonoylglycerol plasma levels in obese subjects. Nutr Metab (Lond) 2011;8(1):7
114. Piscitelli F, Carta G, Bisogno T, et al. Effect of dietary krill oil supplementation on the endocannabinoidome of metabolically relevant tissues from high-fat-fed mice. Nutr Metab (Lond) 2011;8(1):51
115. Batetta B, Griinari M, Carta G, et al. Endocannabinoids may mediate the ability of (n-3) fatty acids to reduce ectopic fat and inflammatory mediators in obese Zucker rats. J Nutr 2009;139(8):1495-501
116. Liu J, Zhou L, Xiong K, et al. Hepatic cannabinoid receptor-1 mediates dietinduced insulin resistance via inhibition of insulin signaling and clearance in mice. Gastroenterology 2012;142(5):1218-1228 e1211
117. Schuchardt JP, Neubronner J, Kressel G, et al. Moderate doses of EPA and DHA from re-esterified triacylglycerols but not from ethyl-esters lower fasting serum triacylglycerols in statin-treated dyslipidemic subjects: results from a six month randomized controlled trial. Prostaglandins Leukot Essent Fatty Acids 2011;85(6):381-6
118. Buettner C, Muse ED, Cheng A, et al. Leptin controls adipose tissue lipogenesis via central, STAT3-independent mechanisms. Nat Med 2008;14(6):667-75 (Pubitemid 351809549)
119. O'Hare JD, Zielinski E, Cheng B, et al. Central endocannabinoid signaling regulates hepatic glucose production and systemic lipolysis. Diabetes 2011;60(4):1055-62